Publication

Cost-effectiveness of increasing bisphosphonates adherence for osteoporosis in community pharmacies

Van Boven, J. F. M., Oosterhof, P., Hiddink, E. G., Stuurman-Bieze, A. G. G., Postma, M. J. & Vegter, S., 1-Nov-2011, In : Value in Health. 14, 7, p. 310 1 p.

Research output: Contribution to journalMeeting AbstractAcademic

APA

Van Boven, J. F. M., Oosterhof, P., Hiddink, E. G., Stuurman-Bieze, A. G. G., Postma, M. J., & Vegter, S. (2011). Cost-effectiveness of increasing bisphosphonates adherence for osteoporosis in community pharmacies. Value in Health, 14(7), 310. https://doi.org/10.1016/j.jval.2011.08.428

Author

Van Boven, J.F.M. ; Oosterhof, P. ; Hiddink, E.G. ; Stuurman-Bieze, A.G.G. ; Postma, M.J. ; Vegter, S. / Cost-effectiveness of increasing bisphosphonates adherence for osteoporosis in community pharmacies. In: Value in Health. 2011 ; Vol. 14, No. 7. pp. 310.

Harvard

Van Boven, JFM, Oosterhof, P, Hiddink, EG, Stuurman-Bieze, AGG, Postma, MJ & Vegter, S 2011, 'Cost-effectiveness of increasing bisphosphonates adherence for osteoporosis in community pharmacies', Value in Health, vol. 14, no. 7, pp. 310. https://doi.org/10.1016/j.jval.2011.08.428

Standard

Cost-effectiveness of increasing bisphosphonates adherence for osteoporosis in community pharmacies. / Van Boven, J.F.M.; Oosterhof, P.; Hiddink, E.G.; Stuurman-Bieze, A.G.G.; Postma, M.J.; Vegter, S.

In: Value in Health, Vol. 14, No. 7, 01.11.2011, p. 310.

Research output: Contribution to journalMeeting AbstractAcademic

Vancouver

Van Boven JFM, Oosterhof P, Hiddink EG, Stuurman-Bieze AGG, Postma MJ, Vegter S. Cost-effectiveness of increasing bisphosphonates adherence for osteoporosis in community pharmacies. Value in Health. 2011 Nov 1;14(7):310. https://doi.org/10.1016/j.jval.2011.08.428


BibTeX

@article{fc45e676c0a74b34829f51dcb8f446a6,
title = "Cost-effectiveness of increasing bisphosphonates adherence for osteoporosis in community pharmacies",
abstract = "OBJECTIVES: Increasing real-life adherence to bisphosphonates therapy is important to achieve the clinical benefits of reducing fractures reported in randomized clinical trials (RCTs). The aim of this pharmacoeconomic analysis was to determine the cost-effectiveness of a pharmaceutical care intervention program in community pharmacies, aimed to increase bisphosphonates adherence for the prevention of osteoporotic fractures. METHODS: A decision analytical model was constructed with a time horizon of three years, discounting at 4.0{\%} and 1.5{\%} annually for costs and effects, respectively. A Dutch healthcare provider's perspective was adopted. Adherence and efficacy data were gathered from a Dutch pharmaceutical care program in community pharmacies (the MeMO intervention). The association between bisphosphonate adherence and osteoporotic fractures was modelled using Dutch clinical studies. Recent and upcoming reimbursement policy changes in The Netherlands were modelled with a scenario of therapeutic substitution, characterized by drastically lower drug prices. RESULTS: Adherence to bisphosphonates therapy in The Netherlands was 68.3{\%}. The pharmaceutical care intervention program increased bisphosphonates adherence to 83.9{\%} (P",
keywords = "bisphosphonic acid derivative, community, pharmacy, cost effectiveness analysis, osteoporosis, pharmaceutical care, fragility fracture, therapy, policy, fracture, cost control, Netherlands, human, quality adjusted life year, model, health care personnel, clinical study, reimbursement, clinical trial (topic), pharmacoeconomics, prevention, drug therapy",
author = "{Van Boven}, J.F.M. and P. Oosterhof and E.G. Hiddink and A.G.G. Stuurman-Bieze and M.J. Postma and S. Vegter",
year = "2011",
month = "11",
day = "1",
doi = "10.1016/j.jval.2011.08.428",
language = "English",
volume = "14",
pages = "310",
journal = "Value in Health",
issn = "1098-3015",
publisher = "ELSEVIER SCIENCE INC",
number = "7",

}

RIS

TY - JOUR

T1 - Cost-effectiveness of increasing bisphosphonates adherence for osteoporosis in community pharmacies

AU - Van Boven, J.F.M.

AU - Oosterhof, P.

AU - Hiddink, E.G.

AU - Stuurman-Bieze, A.G.G.

AU - Postma, M.J.

AU - Vegter, S.

PY - 2011/11/1

Y1 - 2011/11/1

N2 - OBJECTIVES: Increasing real-life adherence to bisphosphonates therapy is important to achieve the clinical benefits of reducing fractures reported in randomized clinical trials (RCTs). The aim of this pharmacoeconomic analysis was to determine the cost-effectiveness of a pharmaceutical care intervention program in community pharmacies, aimed to increase bisphosphonates adherence for the prevention of osteoporotic fractures. METHODS: A decision analytical model was constructed with a time horizon of three years, discounting at 4.0% and 1.5% annually for costs and effects, respectively. A Dutch healthcare provider's perspective was adopted. Adherence and efficacy data were gathered from a Dutch pharmaceutical care program in community pharmacies (the MeMO intervention). The association between bisphosphonate adherence and osteoporotic fractures was modelled using Dutch clinical studies. Recent and upcoming reimbursement policy changes in The Netherlands were modelled with a scenario of therapeutic substitution, characterized by drastically lower drug prices. RESULTS: Adherence to bisphosphonates therapy in The Netherlands was 68.3%. The pharmaceutical care intervention program increased bisphosphonates adherence to 83.9% (P

AB - OBJECTIVES: Increasing real-life adherence to bisphosphonates therapy is important to achieve the clinical benefits of reducing fractures reported in randomized clinical trials (RCTs). The aim of this pharmacoeconomic analysis was to determine the cost-effectiveness of a pharmaceutical care intervention program in community pharmacies, aimed to increase bisphosphonates adherence for the prevention of osteoporotic fractures. METHODS: A decision analytical model was constructed with a time horizon of three years, discounting at 4.0% and 1.5% annually for costs and effects, respectively. A Dutch healthcare provider's perspective was adopted. Adherence and efficacy data were gathered from a Dutch pharmaceutical care program in community pharmacies (the MeMO intervention). The association between bisphosphonate adherence and osteoporotic fractures was modelled using Dutch clinical studies. Recent and upcoming reimbursement policy changes in The Netherlands were modelled with a scenario of therapeutic substitution, characterized by drastically lower drug prices. RESULTS: Adherence to bisphosphonates therapy in The Netherlands was 68.3%. The pharmaceutical care intervention program increased bisphosphonates adherence to 83.9% (P

KW - bisphosphonic acid derivative

KW - community

KW - pharmacy

KW - cost effectiveness analysis

KW - osteoporosis

KW - pharmaceutical care

KW - fragility fracture

KW - therapy

KW - policy

KW - fracture

KW - cost control

KW - Netherlands

KW - human

KW - quality adjusted life year

KW - model

KW - health care personnel

KW - clinical study

KW - reimbursement

KW - clinical trial (topic)

KW - pharmacoeconomics

KW - prevention

KW - drug therapy

U2 - 10.1016/j.jval.2011.08.428

DO - 10.1016/j.jval.2011.08.428

M3 - Meeting Abstract

VL - 14

SP - 310

JO - Value in Health

JF - Value in Health

SN - 1098-3015

IS - 7

ER -

ID: 20494750